Decision: Favourable

Study Title:

A PHASE III, MULTI-CENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES OF ALZHEIMERS’S DISEASE

  • NREC Code:

    22-NREC-CT-072

  • Decision:

    Favourable

  • Meeting Date:

    06/06/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Sean Kennelly

  • PI Institution:

    Tallaght University Hospital

  • Sponsor:

    Roche

Scroll to Top